Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy

current concepts on anti-phospholipase a2 receptor antibody in idiopathic membranous nephropathy.

letter to the editor

Idiopathic membranous nephropathy and anti-phospholipase A2 receptor antibodies.

Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy

Since the identification of PLA2R (M-type phospholipase A2 receptor) as the first human antigenic target in primary membranous nephropathy (MN), perpetual progress has been made in understanding the pathogenesis of this disease. Accumulating clinical data support a pathogenic role for the anti-PLA2R antibodies (PLA2R ABs), but confirmation in an animal model is still lacking. However, PLA2R ABs...

Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: a new personalized medical approach.

Medical care is entering into a new phase of “personalized” medical care in which diagnosis and management are tailored to the specific aspects of individual patients. This approach is often guided by the results of sophisticated biomarkers of disease, prognosis, or treatment responsiveness. In this issue of CJASN, Bech and coworkers from the Radboud University Medical Center (Nijmegen, The Net...

Anti-phospholipase A2 receptor antibody in membranous nephropathy.

The M-type phospholipase A2 receptor (PLA2R) is a target autoantigen in adult idiopathic membranous nephropathy (MN), but the prevalence of autoantibodies against PLA2R is unknown among Chinese patients with MN. Here, we measured anti-PLA2R antibody in the serum of 60 patients with idiopathic MN, 20 with lupus-associated MN, 16 with hepatitis B (HBV)-associated MN, and 10 with tumor-associated ...